May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Daclizumab for Active, Non-Infectious, Sight-Threatening Uveitis: A Phase II Pilot Study
Author Affiliations & Notes
  • S. Yeh
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • K. K. Wroblewski
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • R. Buggage
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Z. Li
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • S. K. Kurup
    Ophthalmology, Wake Forest, Salem, North Carolina
  • H. N. Sen
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • S. Dahr
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • J. Ragheb
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • T. A. Waldmann
    National Cancer Institute/National Institutes of Health, Bethesda, Maryland
  • R. B. Nussenblatt
    Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  S. Yeh, None; K.K. Wroblewski, None; R. Buggage, None; Z. Li, None; S.K. Kurup, None; H.N. Sen, None; S. Dahr, None; J. Ragheb, None; T.A. Waldmann, None; R.B. Nussenblatt, None.
  • Footnotes
    Support  NIH Intramural Funding
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Yeh, K. K. Wroblewski, R. Buggage, Z. Li, S. K. Kurup, H. N. Sen, S. Dahr, J. Ragheb, T. A. Waldmann, R. B. Nussenblatt; Daclizumab for Active, Non-Infectious, Sight-Threatening Uveitis: A Phase II Pilot Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : This study was designed to provide preliminary data regarding the safety and efficacy of high-dose humanized anti-IL-2 receptor (daclizumab) therapy for the treatment of active intermediate, posterior or panuveitis.

Methods: : Five patients were recruited into this non-randomized, prospective pilot study of high-dose intravenous induction daclizumab therapy (8 mg/kg at day 0, 4 mg/kg at day 14). Patients who did not meet a safety endpoint at the 3-week follow-up were given the option of continuing therapy with subcutaneous daclizumab 2 mg/kg for 52 weeks. The primary outcome assessed was a 2-step decrease in vitreous haze at the day 21 follow-up visit. Secondary outcomes included visual acuity, cystoid macular edema, retinal vascular sheathing leakage by fluorescein angiography, anterior chamber and vitreous cellular inflammation, and vitreous haze.

Results: : 4 male patients and 1 female patient were enrolled. Diagnoses included birdshot retinochoroidopathy (2 pts), Vogt-Koyanagi-Harada’s disease, bilateral idiopathic panuveitis and bilateral idiopathic intermediate uveitis. By week 4, four of five patients demonstrated a 2-step decrease in vitreous haze. One participant did not meet this criteria until week 20, but all 5 patients maintained stability in vitreous haze grade throughout their follow-up periods. At enrollment, mean visual acuity (10 eyes in five patients) was 69.2 ETDRS letters and following treatment was 78.2 letters (p=0.08). Anterior chamber cell, vitreous cell, and vitreous haze also improved in the majority of eyes. Specifically, anterior chamber cells decreased in 8 of 9 eyes (88%), vitreous cell decreased in 6 of 10 eyes (60%) and vitreous haze decreased in 8 of 8 eyes. Adverse events were generally mild except for one episode of left-lower lobe pneumonia requiring hospitalization and treatment.

Clinical Trial: : www.clinicaltrials.gov NCT00070759

Keywords: uveitis-clinical/animal model • autoimmune disease • uvea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×